NEO Relative Valuation
NEO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NEO is overvalued; if below, it's undervalued.
Historical Valuation
Neogenomics Inc (NEO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of 36.24. The fair price of Neogenomics Inc (NEO) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 6.24 USD , Neogenomics Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：6.24
Fair
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.96
P/B
Median3y
1.82
Median5y
3.11
-3.74
FCF Yield
Median3y
-3.86
Median5y
-3.28
Competitors Valuation Multiple
The average P/S ratio for NEO's competitors is 0.74, providing a benchmark for relative valuation. Neogenomics Inc Corp (NEO) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 7.55%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Neogenomics Inc (NEO) currently overvalued or undervalued?
What is Neogenomics Inc (NEO) fair value?
How does NEO's valuation metrics compare to the industry average?
What is the current P/B ratio for Neogenomics Inc (NEO) as of Jul 19 2025?
What is the current FCF Yield for Neogenomics Inc (NEO) as of Jul 19 2025?
What is the current Forward P/E ratio for Neogenomics Inc (NEO) as of Jul 19 2025?